Portal de Periódicos da CAPES

Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives

1993; Wiley; Volume: 60; Issue: 5 Linguagem: Inglês

10.1111/j.1471-4159.1993.tb13381.x

1471-4159

Paul T. Francis, Neil R. Sims, Andrew Procter, David M. Bowen,

Neuroscience and Neuropharmacology Research

Journal of NeurochemistryVolume 60, Issue 5 p. 1589-1604 Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives Paul T. Francis, Paul T. Francis Miriam Marks Department of Neurochemistry, Institute of Neurology, Queen Square, London, EnglandSearch for more papers by this authorNeil R. Sims, Neil R. Sims Department of Medical Biochemistry and Centre for Neuroscience, Flinders University of South Australia, Adelaide, AustraliaSearch for more papers by this authorAndrew W. Procter, Andrew W. Procter Miriam Marks Department of Neurochemistry, Institute of Neurology, Queen Square, London, England Department of Psychiatry, United Medical and Dental Schools (Guy's Campus), London, EnglandSearch for more papers by this authorDavid M. Bowen, Corresponding Author David M. Bowen Department of Medical Biochemistry and Centre for Neuroscience, Flinders University of South Australia, Adelaide, AustraliaAddress correspondence and reprint requests to Dr. D. M. Bowen at Miriam Marks Department of Neurochemistry, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, U.K.Search for more papers by this author Paul T. Francis, Paul T. Francis Miriam Marks Department of Neurochemistry, Institute of Neurology, Queen Square, London, EnglandSearch for more papers by this authorNeil R. Sims, Neil R. Sims Department of Medical Biochemistry and Centre for Neuroscience, Flinders University of South Australia, Adelaide, AustraliaSearch for more papers by this authorAndrew W. Procter, Andrew W. Procter Miriam Marks Department of Neurochemistry, Institute of Neurology, Queen Square, London, England Department of Psychiatry, United Medical and Dental Schools (Guy's Campus), London, EnglandSearch for more papers by this authorDavid M. Bowen, Corresponding Author David M. Bowen Department of Medical Biochemistry and Centre for Neuroscience, Flinders University of South Australia, Adelaide, AustraliaAddress correspondence and reprint requests to Dr. D. M. Bowen at Miriam Marks Department of Neurochemistry, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, U.K.Search for more papers by this author First published: May 1993 https://doi.org/10.1111/j.1471-4159.1993.tb13381.xCitations: 167Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES Akiyama H., McGeer P. L., Itagaki S., McGeer E. G., and Kaneko T. (1989) Loss of glutaminase-positive cortical neurons in Alzheimer's disease. Neurochem. Res. 14, 353– 358. Alkon D. L., Amaral D. G., Bear M. F., Black J., Carew T. J., Cohen N. J., Disterhoft J. F., Eichenbaum H., Golski S., Gorman L. K., Lynch G., McNaughton B. L., Mishkin M., Moyer J. R., Olds J. L., Olton D. S., Otto T., Squire L. R., Staubli U., Thompson L. T., and Wible C. (1991) Learning and memory. Brain Res. Rev. 16, 193– 220. Altschuler R. A., Monaghan D. T., Haser W. G., Wenthold R. J., Curtoys N. P., and Cotman C. W. (1985) Immunocytochemical localisation of glutaminase-like and aspartate aminotransferase-like immunoreactivities in the rat and guinea-pig hippocampus. Brain Res 330, 225– 233. Anderson K. J., Bridges R. J., and Cotman C. W. (1991) Increased density of excitatory amino acid transport sites in the hippocampal formation following an entorhinal lesion. Brain Res. 562, 285– 290. Araneda R. and Andrade R. (1991) 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40, 399– 412. Baughman R. W. and Gilbert C. D. (1981) Aspartate and glutamate as possible neurotransmitters in the visual cortex. J. Neurosci. 1, 427– 439. Beal M. F. (1992) Does impairment of energy-metabolism result in excitotoxic neuronal death in neurodegenerative illnesses Ann. Neurol. 31 119– 130. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J., and Martin J. B. (1986a) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321 168– 172. Beal M. F., Mazurek M. F., Chattha G. K., Svendsen C. N., Bird E. D., and Martin J. B. (1986b) Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Ann. Neurol. 20 282– 288. Beal M. F., Clevens R. A., Chattha G. K., MacGarvey U. M., Mazurek M. F., and Gabriel S. M. (1988) Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex. J. Neurochem. 51, 1935– 1941. Benson D. F., Kuhl D. E., Phelps M. E., Cummings J. L., and Tsai S. Y. (1983) The fluorodeoxyglucose 18F scan in Alzheimer and multi-infarct dementia. Arch. Neurol. 40, 711– 714. Bernays R. L., Heeb L., Cuenod M., and Streit P. (1988) Afferents to the rat red nucleus studied by means ofD-[3H]aspartate, [3H]choline and non-selective tracers. Neuroscience 26, 601– 619. Bird E. D., Gale J. S., and Spokes E. G. S. (1977) Huntington's chorea: postmortem activity of enzymes involved in cerebral glucose metabolism. J. Neurochem. 29, 539– 545. Bjork L., Cornfield L. J., Nelson D. L., Hillver S. E., Anden N. E., Lewander T., and Hacksell U. (1991) Pharmacology of the novel 5-hydroxytryptamine 1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J. Pharmacol. Exp. Ther. 258, 58– 65. Bowen D. M. (1983) Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease, in Biological Aspects of Alzheimer's Disease, Banbury Report 15 ( R. Katzman, ed). pp. 219– 231.Cold Spring Harbor Laboratory. Cold Spring Harbor . New York . Bowen D. M., Smith C. B., White P., Flack R. H. A., Carrasco L. H., Gedge J. L., and Davison A. N. (1977) Chemical pathology of the organic dementia. II. Quantitative estimation of cellular changes in post-mortem brains. Brain 100, 427– 453. Bowen D. M., White P., Spillane J. A., Goodhardt M. J., Curzon G., Iwangoff P., Meier-Ruge W., and Davison A. N. (1979) Accelerated ageing or selective neuronal loss as an important cause of dementia Lancet 1 11– 14. Bowen D. M., Allen S. J., Benton J. S., Goodhardt M. J., Haan E. A., Palmer A. M., Sims N. R., Smith C. C. T., Spillane J. A., Esiri M. M., Neary D., Snowden J. S., Wilcock G. K., and Davison A. N. (1983) Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J. Neurochem. 41, 266– 272. Bowen D. M., Francis P. T., Pangalos M. N., Stephens P. H., and Procter A. W. (1992) Treatment strategies for Alzheimer's disease. Lancet 339, 132– 133. Braak H. and Braak E. (1985) On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and lamina-specific pathology in Alzheimer's disease. Acta Neuropathol. 68, 325– 332. Braak H. and Braak E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239– 259. Brun A. (1983) An overview of light and electron microscopic changes, in Alzheimer's Disease: The Standard Reference ( B. Reisberg, ed), pp. 37– 47. Free Press, New York . Caporaso G. L., Gandy S. E., Buxbaum J. D., Ramaghadran T. V., and Greengard P. (1992) Protein phosphorylation regulates secretion of Alzheimer B/A4 amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 89, 3055– 3059. Carli M. and Samanin R. (1992) 8-Hydroxy-2-(di-n-propylamino)-tetralin impairs spatial learning in a water maze: role of postsynaptic 5-HT1A receptors. Br. J. Pharmacol. 105, 720– 726. Chase T. N., Foster N. L., Fedio P., Brooks R., Mansi L., and Di Chiro G. (1984) Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann. Neurol. 15 (Suppl.), S170– S174. Chawluk J. B., Alavi A., Dann R., Hurtig H. I., Bais S., Kushner M. J., Zimmerman R. A., and Reivich M. J. (1987) Positron emission tomography in aging and dementias: effect of cerebral atrophy. J. Nucl. Med. 28, 431– 437. Chessell I. P., Procter A. W., Francis P. T., and Bowen D. M. (1991) D-Cycloserine, a putative cognitive enhancer, facilitates activation of the NMDA receptor-ionophore complex in Alzheimer brain. Brain Res. 565, 345– 348. Christensen I. T., Reinhardt A., Nielsen B., Ebert B., Madsen U., and Krogsgaard-Larsen P. (1989) Excitatory amino acid agonists and partial agonists. Drug Des. Deliv. 5, 57– 71. Christie M. J., Summers R. J., Stephenson J. A., Cook C. J., and Beart P. M. (1987) Excitatory amino acid projections to the nucleus accumbens septi in the rat: a retrograde transport study utilising d-[3H]aspartate and [3H]GABA. Neuroscience 22, 425– 439. Colino A. and Halliwell J. V. (1987) Differential modulation of three separate K-conductances in hippocampal CA1 neurones by serotonin. Nature 328, 73– 77. Collingridge G. L. (1987) NMDA receptors—their role in long term potentiation. Trends Neurosci. 10, 288– 293. Collingridge G. L. and Singer W. (1990) Excitatory amino acid receptors and synaptic plasticity, in TIPS Special Report: Pharmacology of Excitatory Amino Acids ( G. Collingridge and D. Lodge, eds). pp. 42– 53.Elsevier, Cambridge . Conti F., Fabri M., and Manzoni T. (1988) Glutamate-positive corticocortical neurons in the somatic sensory areas I and II of cats. J. Neurosci. 8, 2948– 2960. Copani A., Koh J. Y., and Cotman C. W. (1991) β-Amyloid increases neuronal susceptibility to injury by glucose deprivation. NeuroReport 2, 763– 765. Corsellis J. A. N.(1962) Mental Illness and the Aging Brain. Oxford University Press, Oxford . Crapper-McLachlan D. R., Dalton A. J., Kruck T. P. A., Bell M. Y., Smith W. L., Kalow W., and Andrews D. F. (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304– 1308. Crino P. B., Vogt B. A., Volicer L., and Wiley R. G. (1990) Cellular localization of serotonin 1A, 1B and uptake sites in cingulate cortex in the rat. J. Pharmacol. Exp. Ther. 252, 651– 657. Cross A. J., Skan W. J., and Slater P. (1986) The association of [3H]-d-aspartate binding and high-affinity glutamate uptake in the human brain. Neurosci. Lett. 63, 121– 124. Cutler N. R., Haxby J. V., Duara R., Grady C. L., Kay A. D., Kessler R. M., Sundram M., and Rapoport S. (1985) Clinical history, brain metabolism and neuropsychological function in Alzheimer's disease. Ann. Neurol. 18, 298– 309. Danbolt N. C. and Storm-Mathisen J. (1986) Na+-dependent "binding" of d-aspartate in membranes is largely due to uptake into membrane-bounded saccules. J. Neurochem. 47, 819– 824. Davies M. F., Deisz R. A., Prince D. A., and Peroutka S. J. (1987) Two distinct effects of 5-hydroxytryptamine on single cortical neurones. Brain Res. 423, 347– 352. Davies P. (1991) Therapy for Alzheimer's disease: choosing a target. Clin. Neuropharmacol. 14, S24– S33. DeKosky S. T. and Scheff S. W. (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27, 457– 464. DeSouza E. B., Whitehouse P. J., Kuhar M. J., Price D. L., and Vale W. V. (1986) Reciprocal changes in corticotropin releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature 319, 593– 595. Dewar D., Chalmers D. T., Graham D. I., and McCulloch J. (1991) Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus. Brain Res. 553, 58– 64. Donoghue J. P., Wenthold R. J., and Altschuler R. A. (1985) Localisation of glutaminase-like and aspartate aminotransferase-like immunoreactivity in neurons of cerebral neocortex. J. Neurosci. 5, 2597– 2608. Dudai Y. (1989) The Neurobiology of Memory, pp. 100– 107. Oxford University Press, Oxford . Esiri M. (1991) Neuropathology, in Psychiatry in the Elderly ( R. Jacoby and C. Oppenheimer, eds), pp. 113– 147. Oxford University Press, Oxford . Esiri M. M., Pearson R. C. A., Steele J. E., Bowen D. M., and Powell T. P. S. (1990) A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 53, 161– 165. Ferkany J. and Coyle J. T. (1986) Heterogeneity of sodium dependent excitatory amino acid uptake mechanisms in rat brain. J. Neurosci. Res. 16, 491– 503. Fibiger H. C. (1991) Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci. 14, 220– 223. Fischer B. O., Ottersen O. P., and Storm-Mathisen J. (1991) Axonal transport of d-[3H]-aspartate in the claustrocortical projection. Neuroscience 7 (Suppl.), S69. Fletcher A., Bill D. J., Brammer N. T., Cliffe I. A., Forster Y., and Lloyd G. K. (1991) WAY 100135: a novel and highly selective 5-HT1A receptor antagonist. (Abstr.) Soc. Neurosci. Abstr. 17. 92. Fonnum F. (1984) Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42, 1– 11. Fonnum F., Storm-Mathisen J., and Divac I. (1981) Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 6, 863– 873. Fosse V. M. and Fonnum F. (1987) Biochemical evidence for glutamate and/or aspartate as neurotransmitters in fibres from the visual cortex to the lateral posterior thalamic nucleus (pulvinar) in rats. Brain Res. 400, 219– 224. Francis P. T., Palmer A. M., Sims N. R., Bowen D. M., Davison A. N., Esiri M. M., Neary D., Snowden J. S., and Wilcock G. K. (1985) Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. Engl. J. Med. 313, 7– 11. Francis P. T., Pangalos M. N., and Bowen D. M. (1992a) Animal and drug modelling for Alzheimer synaptic pathology. Prog. Neurobiol. 39 517– 545. Francis P. T., Pangalos M. N., Pearson R. C. A., Middlemiss D. N., Stratmann G. C., and Bowen D. M. (1992) 5-HT1A but not 5-HT2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J. Pharmacol. Exp. Ther. 261 1273– 1281. Francis P. T., Pangalos M. N., Stephens P. H., Bartlett J. R., Bridges P. K., Malizia A. L., Neary D., Procter A. W., Thomas D. J., and Bowen D. M. (1993) Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression. J. Neurol. Neurosurg. Psychiatry (in press). Friston K. J., Grasby P. M., Bench C. J., Frith C. D., Cowen P. J., Liddle P. F., Frackowiak R. S. J., and Dolan R. (1992) Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Netirosci. Lett. 141, 106– 110. Garthwaite G. and Garthwaite J. (1988) Electron microscopic autoradiography of d-[3H]aspartate uptake sites in mouse cerebellar slices shows poor labelling of mossy fibre terminals. Brain Res. 440, 162– 166. Germano I. M., Pitts L. H., Meldrum B. S., Bartkowski H. M., and Simon R. P. (1987) Kynurenate inhibition of cell excitation decreases stroke size and deficits. Ann. Neurol. 22, 730– 734. Gibson G. E., Sheu K.-F. R., Blass J. P., Baker A., Carlson K. C., Harding B., and Perrino P. (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch. Neurol. 45, 836– 840. Girault J. A., Barbeito L., Spampinato U., Gozlan H., Glowinski J., and Besson M.-J. (1986) In vivo release of endogenous amino acids from the rat striatum: further evidence for a role of glutamate and aspartate in corticostriatal neurotransmission. J. Neurochem. 47, 98– 106. Grasby P. M., Friston K. J., Bench C. Cowen, P. J., Frith C. D., Liddle P. F., Frackowiak R. S. J., and Dolan R. J. (1992) Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man. Psychopharmacology 108, 380– 386. Greenamyre J. T. (1991) Neuronal bioenergetic defects, excitotoxicity and Alzheimer's disease—use it and lose it. Neurobiol. Aging 12, 334– 336. Greenamyre J. T. and Young A. B. (1989) Excitatory amino acids in Alzheimer's disease. Neurobiol. Aging 10, 593– 602. Greenamyre J. T., Higgins D. S., and Young A. B. (1990) Sodium-dependent d-aspartate binding is not a measure of presynaptic neuronal uptake sites in an autoradiographic assay. Brain Res. 511 310– 318. Gustafson L., Edvinsson L., Dahlgren N., Hagberg B., Risberg J., Rosen I., and Ferno H. (1987) Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology 93, 31– 35. Handelmann G. E., Nevins M. E., Mueller L. L., Arnolde S. M., and Cordi A. A. (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnesic rodents. Pharmacol. Biochem. Behaw 34, 823– 828. Hardy J. A. and Higgins G. A. (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184– 185. Hassler R., Haug P., Nitsch C., Kim J. S., and Paik K. (1982) Effect of motor and premotor cortex ablation on concentrations of amino acids, monoamines, and acetylcholine and on the ultra-structure in rat striatum. A confirmation of glutamate as the specific cortico-striatal transmitter. J. Neurochem. 38, 1087– 1098. Herrling P. L. (1985 Pharmacology of the corticocaudate excitatory postsynaptic potential in the cat: evidence for its mediation by quisqualate and kainate receptors. Neuroscience 14 417– 426. Hof P. R., Cox K., and Morrison J. H. (1990) Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease. I. Superior frontal and inferior temporal cortex. J. Comp. Neurol. 30, 44– 54. Hyman B. T., Van Hoesen G. W., and Damasio A. R. (1987) Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann. Neurol. 22, 37– 40. Hyman B. T., Van Hoesen G. W., and Damasio A. R. (1990) Memory-related neural systems in Alzheimer's disease: an anatomic study. Neurology 40, 1721– 1730. Iwangoff P., Armbruster R., Enz A., Meier-Ruge W., and Sandoz P. (1980) Glycolytic enzymes from human autopic brain cortex: normally aged and demented cases, in Biochemistry of Dementia ( P. J. Roberts, ed). pp. 258– 262.Wiley. Chichester . Johnson J. L. (1977) Glutamic acid as a synaptic transmitter in the dorsal sensory neuron: reconsiderations. Life Sci. 20, 1637– 1644. Jones E. G. (1984) Laminar distribution of cortical efferent cells, in Cerebral Cortex: Volume I. Cellular Components of the Cerebral Cortex ( A. Peters and E. G. Jones, eds). pp. 521– 553.Plenum Press. New York . Kaneko T. and Mizuno N. (1988) Immunohistochemical study of glutaminase-containing neurons in the cerebral cortex and thalamus of the rat. J. Comp. Neurol. 267, 590– 602. Kesslak J. P., Nalcioglu O., and Cotman C. W. (1991) Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology 41, 51– 54. Kim J.-S., Hassler R., Haug P., and Paik K.-S. (1977) Effect of frontal cortex ablation on striatal glutamic acid level in rat. Brain Res. 132, 370– 374. Kish S. J., Munir E.-A., Schut L., Leach L., Oscar-Berman M., and Freedman M. (1988) Cognitive deficits in olivopontocerebellar atrophy: implications for the cholinergic hypothesis of Alzheimer's dementia. Ann. Neurol. 24, 200– 206. Koh J.-Y., Yang L. L., and Cotman C. W. (1990) β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533, 315– 320. Korey S. R., Scheinberg L., Terry R., and Stein A. (1961) Studies in presenile dementia. Trans. Am. Neurol. Assoc. 86, 99– 102. Kowall N. W. and Beal M. F. (1991)Glutamate-, glutaminase-, and taurine-immunoreactive neurones develop neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 29 162– 167. Kowall N. W., Beal M. F., Busciglio J., and Duffy L. K. (1991) An in vivo model for the neurodegenerative effects of β-amyloid and protection by substance P. Proc. Natl. Acad. Sci. U.S.A. 88 7247– 7251. Lewis D. A., Cambell M. J., Terry R. D., and Morrison J. H. (1987) Laminar and regional distributions of neurofibrillary tangles and neurite plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices. J. Neurosci. 7, 1799– 1809. Liau L. M., Sleight A. J., Pitha J., and Peroutka S. J. (1991) Characterization of a novel and potent 5-hydroxytryptamine1A receptor antagonist. Pharmacol. Biochem. Behav. 38, 555– 559. Lowe S. L., Francis P. T., Procter A. W., Palmer A. M., Davison A. N., and Bowen D. M. (1988) Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain 111, 785– 799. Lowe S. L., Bowen D. M., Francis P. T., and Neary D. (1990) Antemortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 38, 571– 577. Manahan-Vaughan D., Rowan M. J., and Anwyl R. (1992) Agonist and antagonist effects of 5-HT1A receptor ligands on excitatory synaptic transmission in the rat hippocampus in vivo. Br J. Pharmacol. 107, I P. Martin J. B., Beal M. F., Mazurek M., Kowall N. W., and Growdon J. H. (1988) Some observations on the significance of neurotransmitter changes in Alzheimer's disease, in Aging and the Brain ( R. D. Terry, ed). pp. 129– 148.Raven Press, New York . Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R. E. (1992) β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376– 389. Matute C. and Streit P. (1985) Selective retrograde labelling with d-[3H [aspartate in afferents to the mammalian superior colliculus. J. Comp. Neurol. 241, 34– 49. McCormick D. A. and Williamson A. (1989) Convergence and divergence of neurotransmitter action in human cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 86, 8098– 8102. McEntee W. J. and Crook T. H. (1991) Serotonin, memory, and the aging brain. Psychopharmacology 103, 143– 149. McGeer P. L., McGeer E. G., Akiyama H., and Harrop R. (1990) Regional deficits in cortical metabolism in PET-scanned Alzheimer cases correlate with postmortem biochemical indexes of gliosis and not with choline acetyltransferase. Neurobiol. Aging 11, 260– 261. McGeer P. L., Harada N., Kimura H., McGeer E., and Schulzer M. (1992) Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 3, 146– 149. Miller J. D., De Leon M. J., Ferris S. H., Kluger A., George A. E., Reisberg B., Sachs H. J., and Wolf A. R. (1987) Abnormal temporal lobe response in Alzheimer's disease during cognitive processing as measured by 11C-2-deoxy-d-glueose and PET. J. Cereb. Blood Flow Metab. 7, 248– 251. Mohr E., Bruno G., Foster N., Gillespie M., Cox C., Fedio P., and Chase T. N. (1986) GABA-agonist therapy for Alzheimer's disease. Clin. Neuropharmacol. 9, 257– 263. Monahan J. B., Handelmann G. E., Hood W. F., and Cordi A. A. (1989) d-Cycloserine. a positive modulator of the N-methyl-d-aspartate receptor, enhances performance of learning task in rats. Pharmacol Biochem. Behav. 34, 649– 653. Morris R. G. M., Anderson E., and Lynch G. S. (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature 319, 774– 776. Mouradian M. M., Blin J., Giuffra M., Heuser I. J. E., Baronti F., Ownby J., and Chase N. T. (1991) Somatostatin replacement therapy of Alzheimer dementia. Ann. Neurol. 30, 610– 613. Najlerahim A. and Bowen D. M. (1988) Biochemical measurements in Alzheimer's disease reveal a necessity for improved neuroimaging techniques to study metabolism. Biochem. J. 251, 305– 308. Neary D., Snowden J. S., Mann D. M., Bowen D. M., Sims N. R., Northern B., Yates P. O., and Davison A. N. (1986) Alzheimer's disease: a correlative study. J. Neurol. Neurosurg. Psychiatry 49, 229– 237. Neary D., Snowden J. S., Shields R. A., Burjan A. W., Northern B., Macdermott N., Prescott M. C., and Testa H. J. (1987) Single photon emission tomography using [99m]Tc-HM-PAO in the investigation of dementia. J. Neurol. Neurosurg. Psychiatry 50, 1101– 1109. Nitsch R. M., Slack B. E., Wurtman R. J., and Growdon J. H. (1992) Release of Alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304– 307. Novelli A., Reilly J. A., Lysko P. G., and Henneberry R. C. (1988) Glutamate becomes neurotoxic via the N-methyl-d-asparatate receptor when intracellular energy levels are reduced. Brain Res. 451 205– 212. Ottersen O. P. (1991) Excitatory amino acid neurotransmitters: anatomical systems, in Excitatory Amino Acid Antagonists ( B. S. Meldrum, ed), pp. 14– 38. Blackwell Scientific, Oxford . Palmer A. M. (1987) Central Monoamine Neurones in Alzheimer's Disease, pp. 56– 69. Ph.D. thesis, University of London, London . Palmer A. M. Sims N. R., Bowen D. M., Neary D., Palo J., Wikstrom J., and Davison A. N. (1984) Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J. Neurol, Neurosurg. Psychiatry 47, 481– 484. Palmer A. M., Procter A. W., Stratmann G. C., and Bowen D. M. (1986) Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease. Neurosci. Lett. 66, 199– 204. Palmer A. M., Francis P. T., Benton J. S., Sims N. R., Mann D. M. A., Neary D., Snowden J. S., and Bowen D. M. (1987a) Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J. Neurochem. 48 8– 15. Palmer A. M., Francis P. T., Bowen D. M., Benton J. S., Neary D., Mann D. M., and Snowden J. S. (1987b) Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Res. 414 365– 375. Palmer A. M., Wilcock G. K., Esiri M. M., Francis P. T., and Bowen D. M. (1987c) Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res 401 231– 238. Palmer A. M., Stratmann G. C., Procter A. W., and Bowen D. M. (1988) Possible neurotransmitter basis of behavioural changes in Alzheimer's disease. Ann. Neurol. 23 616– 620. Palmer A. M., Hutson P. H. Lowe S. L., and Bowen D. M. (1989) Extracellular concentrations of aspartate and glutamate in rat neostriatum following chemical stimulation of frontal cortex. Exp. Brain Res. 75, 659– 663. Pangalos M. N., Francis P. T., Middlemiss D. N., Pearson R. C. A., and Bowen D. M. (1991) Selective destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from Adenia volkensii. J Neurosc